LiVeritas Biosciences
LiVeritas Biosciences is revolutionizing drug testing by providing a faster, accurate, and precise biopharma digital twin solution for drug quality, safety, and efficacy. Located in South San Francisco, they offer tailored LC-MS services and a streamlined Mass Spec-as-a-Service (MSaaS) solution to accelerate drug development and approval processes.
Industries
Nr. of Employees
small (1-50)
LiVeritas Biosciences
432 N Canal St Ste 20, South San Francisco, CA 94080, USA
Products
Integrated laboratory automation ecosystem (AI-powered)
An integrated laboratory platform that applies automation and AI to orchestrate lab workflows, integrate LC‑MS data, and accelerate analysis-to-decision timelines.
Integrated laboratory automation ecosystem (AI-powered)
An integrated laboratory platform that applies automation and AI to orchestrate lab workflows, integrate LC‑MS data, and accelerate analysis-to-decision timelines.
Services
Comprehensive laboratory service from project scoping and sample intake through method selection, LC‑MS data acquisition, data processing, interpretation, and results reporting. Offers phase-appropriate projects and accelerated turnaround options.
QC assays and lot release testing aligned to cGMP practices, including physicochemical assays, LC-UV/MS-based peptide mapping, ELISA antigen-binding assessments, and residual host-cell impurity testing with method qualification and validation support.
Method development, pre-validation, reference standard characterization, forced degradation studies, sequence variant analysis, and analytical support for IND filings.
Development of software and informatics to support LC‑MS data processing, workflow orchestration, and an integrated laboratory ecosystem leveraging automation and AI.
Comprehensive laboratory service from project scoping and sample intake through method selection, LC‑MS data acquisition, data processing, interpretation, and results reporting. Offers phase-appropriate projects and accelerated turnaround options.
QC assays and lot release testing aligned to cGMP practices, including physicochemical assays, LC-UV/MS-based peptide mapping, ELISA antigen-binding assessments, and residual host-cell impurity testing with method qualification and validation support.
Method development, pre-validation, reference standard characterization, forced degradation studies, sequence variant analysis, and analytical support for IND filings.
Development of software and informatics to support LC‑MS data processing, workflow orchestration, and an integrated laboratory ecosystem leveraging automation and AI.
Expertise Areas
- LC‑MS analytics
- Biotherapeutic characterization
- Mass spectrometry method development
- cGMP/QC testing and lot release
Key Technologies
- Ultra-high-resolution mass spectrometry
- Liquid chromatography (LC) coupled to MS
- Intact mass analysis
- Peptide mapping
News & Updates
A webinar held on April 6th, 2022, discussing LC-MS strategies for bispecific antibodies.
A seminar at ASMS 2021, details available in the webinars section.
Announcement of the new AI-powered laboratory ecosystem.
Interview with the CEO discussing the company's vision and innovations.
Profile highlighting the CEO's background and leadership.
Details about the launch of their software development branch.
A webinar held on April 6th, 2022, discussing LC-MS strategies for bispecific antibodies.
A seminar at ASMS 2021, details available in the webinars section.
Announcement of the new AI-powered laboratory ecosystem.
Interview with the CEO discussing the company's vision and innovations.
Profile highlighting the CEO's background and leadership.
Details about the launch of their software development branch.